Dr. Janet Shipley
She has previously worked in the DNA Repair Group at the Paediatric Research Unit at Guy’s Hospital in London, the Genetics Division of Harvard at Children’s Hospital in Boston, USA, and the London Research Institute.
She moved to The Institute of Cancer Research, London, to establish a laboratory characterizing genomic rearrangements in tumors and was awarded tenure in 1996. Her lab. has had a long-standing research interest in the molecular biology of rhabdomyosarcomas and ways to improve outcome for patients. She is co-authored more than 160 peer-reviewed manuscripts and is currently a member of the National Cancer Research Institute (NCRI) Clinical Studies Young Onset Sarcoma Subgroup (YOSS), Chair of the Biological Committee for the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) and sits on the Research Advisory Board of the charity Sarcoma UK.
The Focus On Rhabdo Webinar Series continues on July 27th at 2 PM Eastern with Dr. Janet Shipley talking about a double-pronged strategy that uses two experimental cancer drugs together. The combination could successfully treat a childhood cancer by inhibiting tumor growth and blocking off the escape routes it uses to become resistant to treatment. Dr. Shipley’s research team at The Institute of Cancer Research, London, found that combining two separate molecularly targeted therapies could stop processes driving growth in cancer called rhabdomyosarcoma, a major cause of cancer death in children. Further lab work/pre-clinical testing will be required before progression to clinical testing.